Takeaways From UPC's Amgen Patent Invalidity Analysis
On July 16, in Regeneron Pharmaceuticals Inc. v. Amgen Inc., the Unified Patent Court Central Division in Munich delivered its first revocation decision just over a year after the court opened its...To view the full article, register now.
Already a subscriber? Click here to view full article